Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Duovir N Tablet
Manufacturer/Marketed By : CIPLA LTD
$7.09 $6.39
Duovir N Tablet contains the active ingredient Lamivudine + Nevirapine + Zidovudine. It is a combination of three antiretroviral medicines. Lamivudine and Zidovudine mainly belong to the class of medications...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
LAMIVUDINE,NEVIRAPINE,ZIDOVUDINE
Active Pharmaceutical Ingredient
Duovir N Tablet
$7.09
$6.39
Duovir N Tablet contains the active ingredient Lamivudine + Nevirapine + Zidovudine. It is a combination of three antiretroviral medicines. Lamivudine and Zidovudine mainly belong to the class of medications called nucleoside/nucleotide reverse transcriptase inhibitors. Nevirapine belongs to the class of medication called non-nucleoside reverse transcriptase inhibitors. It is used to treat HIV-1 infection. This tablet is not advised for patients with anemia (low red blood cells) or neutropenia (low white blood cells). Inform your doctor if you have any liver disease, including hepatitis B or C, kidney disease, or are overweight. The administration of this tablet is associated with hematologic toxicity (decrease in blood cells), muscle weakness, liver diseases and infection, and lactic acidosis (acid buildup due to problems in the body's metabolism). This medication is not advised for children less than 35 kg. Lamivudine, Nevirapine, and zidovudine tablets may cause decreased fertility in females. Talk to your physician if you have any concerns about fertility. Duovir N Tablet is not recommended if you are allergic to this drug or any other active substance or if you are pregnant or breastfeeding women. Inform your physician if you have liver issues, hepatitis infection, kidney diseases, or undergoing dialysis. Tell your physician if you have any active skin conditions such as rash. This tablet can interact with certain medications, potentially affecting their efficacy or increasing the risk of side effects. It's necessary to inform your doctor about all your medications, including prescription, over-the-counter, and herbal supplements, to ensure no potential interactions.
Active Pharmaceutical Ingredient
Uses
• HIV-1 Infection
Benefits
Duovir N Tablet is a combination of three antiretroviral medicines. Lamivudine and Zidovudine work by inhibiting the reverse transcriptase enzyme of HIV, restricting viral genome replication, and reducing the production of new infectious viral particles. It mainly interferes with reverse transcription and inhibits the spread of HIV. Nevirapine directly binds to reverse transcriptase (RT) and blocks RNA-dependent and DNA-dependent polymerase activities by disrupting the enzyme.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Most Common Side Effects
• Nausea
• Diarrhea
• Headache, dizziness
• Cough
• Difficulty sleeping
Common Side Effects
• Lactic acidosis (breathing difficulties along with weakness in limbs, stomach pain, vomiting, and drowsiness)
• Severe skin reactions and rash (blisters, red or inflamed eyes, swelling of the face, mouth sores, joint aches, fever, tiredness)
• Liver problems (yellowing of skin, eyes, fever, tea-colored urine, light-colored stools, pain in right side of ribs, loss of appetite)
• Osteonecrosis (stiffness and pain in joints, difficulty moving)
• Symptoms of muscle weakness or infection
• Loss of fat from legs, face, and arms
How To Use
Take the Duovir N Tablet as advised by your physician. Swallow the tablets whole and intact. This tablet should be taken with food. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the medicine if your doctor advises you to stop.
Safety Advice
• Breast Feeding: Breastfeeding is not recommended in patients taking Duovir N Tablet because the medicine passes into the breast milk in small amounts and may harm your baby. Do not breastfeed during the treatment.
• Alcohol: It is unknown whether consuming alcohol while taking Duovir N Tablet is safe. Please speak with your physician.
• Liver: Duovir N Tablet should be cautiously used in patients with liver diseases. Dose adjustments are necessary. However, inform your physician of any liver diseases before initiating the therapy.
• Lungs: It is unknown whether Duovir N Tablet is safe for patients with lung diseases. Inform your physician if you have any lung diseases before initiating the therapy.
• Driving: It is unknown whether Duovir N Tablet alters the ability to drive or operate heavy machinery. If you feel sleepy or dizzy, avoid driving and consult your doctor.
• Pregnancy: Do not take Duovir N Tablet if you are in your first trimester because this may harm the unborn baby. Inform your physician if you are pregnant, suspecting, or planning to get pregnant during the treatment.
Disclaimer
Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.
All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.
Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.